跳至主要内容
临床试验/NCT07399431
NCT07399431已完成不适用

Effectiveness of Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia: A Randomized Controlled Trial as a National Model for Comprehensive Management

Indonesia University1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2025年10月19日最近更新:
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
22
试验地点
1
主要终点
Improvement in craving for methamphetamine

研究概览

简要总结

Methamphetamine use disorder (MUD) remains a major public health concern in Indonesia, with limited effective treatment options and high relapse rates. Theta Burst Stimulation (TBS) has emerged as a promising adjunctive intervention for reducing craving and improving clinical outcomes. This trial aims to evaluate the efficacy and safety of TBS for MUD. A RCT of 20 subjects was conducted to evalute the efficacy and safety of TBS as an adjunctive treatment to CBT in managing MUD.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Double-blind

入排标准

年龄范围
18 Years 至 59 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects aged 18-59 years old
  • Subjects diagnosed with methamphetamine use disorder without having undergone treatment, whether psychotherapy and/or psychopharmacological modalities
  • Subjects are able to read and write

排除标准

  • Subjects with severe thought process disorders, impaired perception, restless condition, severe neurological disorders, history of neuromodulation,
  • Subjects refused to participate in the study
  • Subjects who are pregnant
  • Subjects who have radioactive implants

研究组 & 干预措施

TBS and CBT

Experimental

During 12 days of intervention, the participants underwent 10 sessions of TBS and 12 sessions for CBT.

干预措施: Theta Burst Stimulation (Device)

TBS and CBT

Experimental

During 12 days of intervention, the participants underwent 10 sessions of TBS and 12 sessions for CBT.

干预措施: Cognitive Behavioral Therapy (Behavioral)

Sham and CBT

Sham Comparator

During 12 days of intervention, the participants underwent 10 sessions of sham TBS and 12 sessions of CBT.

干预措施: Theta Burst Stimulation (Device)

Sham and CBT

Sham Comparator

During 12 days of intervention, the participants underwent 10 sessions of sham TBS and 12 sessions of CBT.

干预措施: Cognitive Behavioral Therapy (Behavioral)

结局指标

主要结局

Improvement in craving for methamphetamine

时间窗: Baseline (T1), day 3 (T2), day 5 (T3), day 8 (T4), and day 10 (T5)

Cue-induced craving was measured with Visual Analog Scale (VAS) where the patient told to indicate their point of craving in a 100 mm line. The scale ranged from 0 to 10, with higher scores indicated higher craving.

Improvement in craving (tonic) for methamphetamine

时间窗: Baseline (T1), day 3 (T2), day 5 (T3), day 8 (T4), and day 10 (T5)

Tonic or baseline craving was measured using the Questionnaire for Smoking Urges modified for Methamphetamine (QSU-M) in Indonesian version. The questions were self-filled by the participants to identify their level of craving. The QSU-M is a 7-point Likert Scale (1 was strongly disagree and 7 was strongly agree) with the higher total scores indicating higher tonic craving. The total minimum score was 10 while the maximum score was 70.

Improvement in clinical severity

时间窗: Baseline (T1), day 3 (T2), day 5 (T3), day 8 (T4), and day 10 (T5)

The clinical severity was measured using the Clinical Global Impression - Severity by the psychiatrist based on the patient's condition during the day of examination. CGI is a clinician-rated instrument used to assess the patient's condition based on clinical judgment. CGI mainly rates the severity of illness assessed using a 7-point Likert scale, ranges from 1 (normal) to 7 (among the most extremely ill). Higher score indicated higher severity of addiction-related illness.

次要结局

  • Improvement in Addiction Severity(Baseline (T1) and Post-Intervention Day 12 (T6))
  • Improvement in Depressive Symptoms(Baseline (T1) and Post-Intervention Day 12 (T6))
  • Improvement in Motivation to Change(Baseline (T1) and Post-Intervention Day 12 (T6))
  • Improvement in Impulsivity(Baseline (T1) and Post-Intervention Day 12 (T6))
  • Improvement in Sleep Quality(Baseline (T1) and Post-Intervention Day 12 (T6))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kristiana Siste

Dr. dr. Kristiana Siste, Sp.KJ(K) - Head of Department of Psychiatry, Cipto Mangunkusumo General Hospital

Indonesia University

研究点 (1)

Loading locations...

相似试验